The standard of care for individuals diagnosed with advanced and metastatic prostate cancer is androgen deprivation therapy (ADT), sometimes in combination with other androgen receptor (AR)-directed treatments or taxane-based chemotherapy. However, 10–20% of cases progress after androgen deprivation to a more aggressive disease stage known as castration-resistant prostate cancer (CRPC). Unfortunately, various mechanisms of resistance emerge in CRPC, including enrichment of genomic alterations associated with poor prognosis, aberrations that maintain the activation of the AR pathway, and phenotypic transformation into AR-null and neuroendocrine phenotypes. See how researchers demonstrated the ability to automate preclinical testing with prostate cancer organoids with diverse phenotypes.

For research use only. Not for use in diagnostic procedures.